Subject:
- Active Substance: Midostaurin
- Name: Rydapt®
- Therapeutic area: Acute myeloid leukaemia (AML)
- Pharmaceutical company: Novartis Pharma GmbH
Time table:
- Publication of project plan: 20.06.2017
- Publication of final assessment: 08.11.2017
Assessment information:
- Title: Midostaurin for the indication of Acute Myeloid Leukaemia
- Author/Co-Author: FIMEA (Finnland), NOMA (Norway)
- Dedicated Reviewers: TLV (Sweden), ZIN (Netherlands), HAS (France), AEMPS (Spain)
- Information retrieval: IQWIG (Germany)
- Observer: SUKL (Czech Republic), EOPYY (Greece), SESCS (Spain)
› G-BA assessment available (D-319)